TRANSFEROSOMAL NASAL IN SITU GELS: A REVIEW
Pooja A. J.*, Vineetha K., Krishnananda Kamath K. and Shabaraya A. R.
ABSTRACT
The majority of medications are often administered orally or intravenously for quick effect, improved patient
compliance and simplicity of medication administration. However, treating neurodegenerative and mental illnesses
is extremely difficult due to the low bioavailability and restricted brain exposure of medications taken orally. As a
result, the circumstance calls for drug delivery to the brain. Numerous parameters, including molecular weight,
delivery method, drug's lipophilic nature and blood-brain barrier (BBB), are taken into account for brain targeting
(BBB). These elements restrict the drug's ability to enter brain tissue via BBB. One of the potential solutions to
these issues is intranasal medication administration, which avoids the BBB and reduces the dosage while
improving drug exposure in the brain. For a targeted brain delivery system, transferosomes serves as the carrier.
This drug delivery technique uses a precisely engineered artificial vesicle that resembles cell vesicles to distribute
drugs in a regulated and possibly targeted manner. They share a similar phospholipid composition with liposomes,
making them biocompatible and biodegradable. They are composed of edge activators such as sodium cholate,
phospholipids like phosphatidyl choline and a little quantity of ethanol. This article provides a crucial overview of
the characteristics, make-up, production methods, characterisation and uses of transfersomes as drug delivery
vesicles.
Keywords: Transferosomes, Nasal in situ, Brain targeting, Vesicular drug delivery.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
